AUTHOR=Li Qiu-Lin , Tang Jing , Zhao Ling , Ruze Amanguli , Shan Xue-Feng , Gao Xiao-Ming 

TITLE=The role of CD74 in cardiovascular disease

JOURNAL=Frontiers in Cardiovascular Medicine

VOLUME=Volume 9 - 2022

YEAR=2023

URL=https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.1049143

DOI=10.3389/fcvm.2022.1049143

ISSN=2297-055X

ABSTRACT=Leukocyte differentiation antigen 74 (CD74), also known as invariant chain (Ii), is a transmembrane glycoprotein that is non-polymorphic. CD74 acts as a molecular chaperone for MHC class II molecules that are involved in the antigen presentation of exogenous antigens. The MIF/CD74 pathway acts in conjunction with CXCR2 and CXCR4 to act as a chemotactic agent for monocytes and T lymphocytes, thereby contributing to atherosclerosis. CD74 is also a high-affinity receptor for MIF/D-DT, forming receptor complexes with CD44, CXCR2 and CXCR4 to activate various signaling pathways such as AMPK, NF-κB, and ERK, all of which play important regulatory roles in ischemia-reperfusion (I/R) injury, acute myocardial infarction (AMI), pressure overload-induced myocardial hypertrophy, and arrhythmias. Small molecule inhibitors targeting CD74 therapy have also made real progress. In this review, we concentrated on the role of CD74 in cardiovascular diseases.